The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...

The Novo Nordisk Foundation continues to prioritize its focus on non-communicable diseases despite a global health crisis prompted by the U.S. freeze on foreign aid. With substantial assets, the ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

King Frederik stepped out for the official royal engagement to witness the big initiative after announcing his diplomatic ...

As a whole, the list of top 50 most admired companies in 2025 saw four new entrants, namely Caterpillar (#40), ServiceNow ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...